Actively Recruiting
A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease
Led by AstraZeneca · Updated on 2026-05-06
43
Participants Needed
21
Research Sites
185 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to assess the safety, tolerability, pharmacokinetic, and efficacy of surovatamig administered by subcutaneous injection in adult participants with primary membranous nephropathy.
CONDITIONS
Official Title
A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 75 years inclusive at the time of informed consent
- Diagnosis of anti-PLA2R antibody-positive primary membranous nephropathy
- Received standard therapy with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for at least 4 weeks, unless intolerant or contraindicated
- Positive test for anti-PLA2R antibodies
- Up to date with required vaccinations as per institutional guidelines before study entry
- Male and/or female assigned at birth, inclusive of all gender identities, with contraception use according to local regulations
- Capable of giving signed informed consent
You will not qualify if you...
- Received B cell-depleting therapy including CD19- or CD20-directed monoclonal antibodies less than 9 months before screening
- Immunomodulatory therapy less than 3 months before screening
- Secondary causes of membranous nephropathy
- Diabetes with hemoglobin A1C greater than 8.5% at screening
- History of malignancies
- History of hemophagocytic lymphohistiocytosis or macrophage activation syndrome
- Significant central nervous system co-morbidity
- History of chronic significant respiratory disease
- Significant opportunistic infection considered relevant by the investigator
- Abnormal vital signs after 10 minutes sitting at rest
- Use of corticosteroids exceeding 20 mg prednisolone or equivalent less than 2 months before screening
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 21 locations
1
Research Site
Los Angeles, California, United States, 90095
Not Yet Recruiting
2
Research Site
Iowa City, Iowa, United States, 52242
Not Yet Recruiting
3
Research Site
Bethesda, Maryland, United States, 20889
Not Yet Recruiting
4
Research Site
New York, New York, United States, 10016
Not Yet Recruiting
5
Research Site
Houston, Texas, United States, 77027
Actively Recruiting
6
Research Site
Houston, Texas, United States, 77030
Not Yet Recruiting
7
Research Site
Ieper, Belgium, 8900
Not Yet Recruiting
8
Research Site
Bordeaux, France, 33076
Not Yet Recruiting
9
Research Site
Créteil, France, 94010
Withdrawn
10
Research Site
Lyon, France, 69009
Not Yet Recruiting
11
Research Site
Nantes, France, 44093
Not Yet Recruiting
12
Research Site
Nîmes, France, 30029
Not Yet Recruiting
13
Research Site
Düsseldorf, Germany, 40225
Not Yet Recruiting
14
Research Site
Brescia, Italy, 25123
Not Yet Recruiting
15
Research Site
Rozzano, Italy, 20089
Not Yet Recruiting
16
Research Site
Torino, Italy, 10154
Not Yet Recruiting
17
Research Site
Verona, Italy, 37126
Withdrawn
18
Research Site
Lodz, Poland, 92-213
Not Yet Recruiting
19
Research Site
Barcelona, Spain, 08025
Not Yet Recruiting
20
Research Site
Madrid, Spain, 28041
Not Yet Recruiting
21
Research Site
Manchester, United Kingdom, M13 9WL
Not Yet Recruiting
Research Team
A
AstraZeneca Clinical Study Information Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here